Best Grants for Cancer Nonprofits in American Samoa

The National Cancer Institute's STRIPE program aims to advance cancer therapy by investigating the effects of radionuclide-emitted radiation. This initiative encourages multidisciplinary research to understand how radiation impacts normal tissues and tumor cells, ultimately improving therapeutic outcomes. By consolidating various funding mechanisms, STRIPE seeks to lower entry barriers for researchers, enhance the scientific foundation of radiopharmaceutical therapy, and foster innovative treatment strategies. Projects can be exploratory or research-focused, with flexible timelines for completion.

The NCI Worta McCaskill-Stevens Career Development Award supports new clinicians committed to research in community oncology and cancer prevention. This funding aims to facilitate their transition to independent research careers and advanced funding mechanisms. Scholars can lead independent community-based clinical trials, conduct ancillary studies, or gain valuable research experience, specifically targeting underserved communities. Applications are due by 5:00 PM local time of the applicant's organization.

The Canine Cancer Immunotherapy Network (K9CIN) aims to advance canine cancer treatments through innovative clinical trials, paralleling the development of human therapies. This initiative is vital as pet dogs naturally develop cancer, mirroring human responses to treatments. By leveraging NIH support, K9CIN will facilitate research to enhance immunotherapeutic strategies for both dogs and humans, fostering a collaborative environment for veterinary and human medical advancements. Ultimately, this funding opportunity promotes ethical research that benefits both species.

This funding opportunity aims to bolster the cancer surveillance workforce through educational initiatives. By enhancing collaborations with cancer partners and developing tools for improved data quality, this program will expand the capacity of registrars. Efforts will focus on recruitment and retention, ultimately ensuring compliance with Public Law 102-515. Strengthening the cancer registrar workforce will lead to timely and accurate cancer data submission, supporting public health objectives.

The National Cancer Institute (NCI) invites applications for the Toward Translation of Nanotechnology Cancer Interventions (TTNCI) program. This funding opportunity focuses on advanced pre-clinical research aimed at developing nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards will support the maturation of innovative nanomedicines using nanoparticles and nano-devices, enhancing cancer treatment efficacy. Successful projects will progress towards further NCI translational programs, such as the NExT initiative.

The NCI Pathway to Independence Award (K99/R00) aims to support talented postdoctoral researchers in their transition to independent faculty positions. This program provides essential NCI research funding to help awardees establish competitive, independent research careers. Applications must be submitted by 5:00 PM local time of the applicant's organization, ensuring timely consideration for this critical funding opportunity.

The FY26 Peer Reviewed Cancer Research Program's Idea Award promotes innovative, high-risk cancer research initiatives. It supports groundbreaking concepts that advance cancer knowledge, patient care, and treatment options within the Military Health System. Projects must demonstrate creativity and innovation, avoiding incremental advancements. Notably, the Early Career Investigator Option is available to foster the growth of promising new investigators early in their careers. This award aims to make significant contributions to cancer research for Service Members and Veterans.

The DoW Peer Reviewed Cancer Clinical Trial Award supports the rapid initiation of clinical trials aimed at significantly improving cancer treatment. Projects may range from small pilot studies to large-scale phase III trials, focusing on innovative products, drugs, or devices. This award mandates the inclusion of patient advocates and prohibits animal studies, ensuring that all preclinical work is completed prior to the award start date. Regulatory applications must be submitted if required for the proposed trials.

The FY26 Peer Reviewed Cancer Research Program Impact Award promotes significant research aimed at enhancing clinical cancer care. It requires preliminary data to ensure feasibility and emphasizes projects with a strong potential for immediate impact. This funding supports clinical trials and allows for either a single Principal Investigator or a duo of partnering PIs, ensuring that both can contribute distinct aspects of the research. Applications must be carefully coordinated to avoid withdrawal risks.

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

The Cancer Center Support Grants (CCSGs) aim to bolster NCI-Designated Cancer Centers through funding that supports diverse research activities. These grants enhance comprehensive, clinical, and basic cancer research while fostering collaboration among institutions. The program prioritizes interdisciplinary approaches to advance cancer prevention, diagnosis, and treatment, ultimately reducing cancer's impact on public health. CCSGs also facilitate resource sharing, administrative support, and the development of innovative research initiatives.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

The National Cancer Institute invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation of assays, emphasizing the importance of human samples. The program encourages multi-disciplinary collaboration and aims to enhance the performance and reproducibility of cancer assays across clinical laboratories. Applications are due by 5:00 PM local time during the designated deadlines each year.

The Exploratory Grant Award aims to enhance workforce diversity in basic cancer research by supporting junior and Early Stage Investigators from underrepresented groups in the biomedical and social sciences. This initiative provides essential funding to bridge the gap for researchers completing their training, ensuring they have the resources needed to develop larger grant applications. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submissions.

The DoW Rare Cancers Concept Award for FY26 promotes groundbreaking ideas in rare cancer research. This award encourages innovative applications that explore novel courses of investigation without requiring preliminary data. Unique to this program is the prohibition against mentioning the Principal Investigator or collaborators in the proposal materials, ensuring an unbiased review process. This funding opportunity aims to advance scientific discovery in the rare cancer domain.

The Cancer Research Education Grants Program (R25) aims to enhance research education in areas crucial to the NIH mission. This program supports innovative courses that develop skills in cancer research, covering topics such as prevention, diagnosis, and treatment. Grant applications are encouraged to be creative and state-of-the-art, addressing the needs of patients and their families. Key deadlines for applications span from January 2024 to September 2026, ensuring ongoing support for educational initiatives.

The International Development and Education Award (IDEA) supports early-career oncologists in low- and middle-income countries, enhancing their expertise through mentorship and participation in the ASCO Annual Meeting. Recipients benefit from long-term professional relationships and access to resources such as the Journal of Clinical Oncology. Additionally, the IDEA-PC program focuses on medical education in palliative care, fostering knowledge sharing and collaboration to improve cancer care in their home countries.

The Tobacco, Alcohol, and Cannabis Policy Research for Health Equity grant aims to support research on policies affecting tobacco, alcohol, and cannabis use in the U.S. This initiative focuses on how these policies impact populations facing health disparities. Key components include engaging community organizations to advance equity in cancer prevention. Important deadlines for applications range from February 2025 to October 2027, providing opportunities for both standard and renewal submissions.

The Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional) aims to fund projects that explore policies related to tobacco, alcohol, and cannabis in the U.S. The focus is on understanding how these policies affect usage and exposure among disadvantaged populations. Engaging community organizations is essential for promoting equity in cancer prevention. This initiative is crucial for advancing health equity and reducing disparities in substance use.

This funding opportunity invites applications for R01 grants focused on molecular imaging methods to explore cancer inflammation in vivo. It aims to enhance understanding of dynamic interactions between inflammation and cancer through innovative imaging techniques. The initiative encourages collaborations between cancer researchers and imaging scientists to leverage molecular imaging for identifying cellular physiology changes in response to treatment. Deadline dates for applications range from February 2025 to October 2027, emphasizing timely submission for prospective researchers.

The Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) aims to enhance cancer treatment by integrating imaging and liquid biopsy assays. This initiative, led by the National Cancer Institute (NCI), encourages grant applications focused on assessing therapy responses and resistance emergence in patients. Key deadlines for submissions span from February 2025 to January 2028, providing ample opportunities for researchers to contribute to this vital area of cancer research.

The Academic Research Enhancement Award (AREA) supports small-scale research grants for institutions with limited NIH funding, emphasizing biomedical research experiences for undergraduates. Eligible institutions must award baccalaureate science degrees and have received no more than $6 million in NIH support over the past seven years. This initiative aims to enhance the research environment at these institutions, fostering student involvement in research activities.

The National Cancer Institute (NCI) invites applications for the validation of molecular, cellular, and imaging markers for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation phases, emphasizing multi-disciplinary collaboration. The UH2 phase focuses on analytical validation, while the UH3 phase extends to clinical validation using well-annotated biospecimens. Proposals should justify the relevance of assays for clinical use and may include harmonization efforts across laboratories.